Ractigen Therapeutics is an early-stage pharmaceutical company committed to bringing to market first-in-class therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells. Its core technology is based on a paradigm-shifting discovery made at the University of California San Francisco (UCSF) known as RNA activation (RNAa). Founded in 2016 by the pioneers in the field, Ractigen is developing a rich pipeline of candidate medicines for patients with unmet need.
About the name Ractigen: Ractigen (răk’tijən) signifies RNA activates genes.
Ractigen Therapeutics has raised 50 million RMB (~8 million USD) in venture financing and occupies a 2400-sqr meter, four-storied building in the modern Industry Park of Life and Health Science of Rudong, Jiangsu, China.
Ractigen Therapeutics's platform is based on a technology called RNAa (RNA activation) that utilizes small RNA duplexes to specifically target and up-regulate therapeutic genes. RNAa represents one of the few available technologies that could be translated into the clinic to treat disease by stimulating the production of endogenous genes. RNAa holds great promise for treating a wide variety of diseases including those undruggable by conventional therapies. The therapeutic benefits of RNAa have been demonstrated in a number of preclinical studies carried out in different disease models.
Ractigen Therapeutics is an early-stage biopharmaceutical company committed to bringing to market first-in-class products for the treatment of a wide variety of diseases, with a focus on cancer and debilitating genetic diseases. Founded in 2016, Ractigen is developing a rich pipeline of candidates with our most advanced product candidate entering IND-enabling development.
More infosRactigen Therapeutics is led by a cohesive team of scientists and professionals with a broad background in RNA research and drug development including the inventors of RNAa technology, nucleic acid chemists, biotech entrepreneurs and experts in drug discovery.
Thursday, January 27, 2022 fundraising
[01/27/2022, Nantong] Ractigen Therapeutics today announced the closing of a Series A+ financing round totaling $30 million led by SDIC Venture Capital with participation from Eisai Co., Ltd., LC Ventures, CSSD Capital, and Xianghe Capital. This capital will be used to advance...
Monday, August 2, 2021 News
[August 2ed, 2021] According to an article published by CB Insights China, Ractigen Therapeutics is listed as one of the 9 RNA companies that can influence the future of the RNA therapeutics industry in China. This is the second time that Ractigen was mentioned by CB Insights China. The agency...
Wednesday, February 10, 2021 News
[2/11/2021, Nantong] Ractigen Therapeutics, a leading company in the saRNA drug space, announced that it has closed a 17$ million USD (￥110 million) Series A financing round led by Hillhouse Venture Capital with participation from CCB Healthcare Growth Fund, Boyi Capital, and...
© 2017 Ractigen Therapeutics, all rights reserved
Design and Development by Digital Space